Imugen utilizes various laboratory test methodologies, each designed and refined to best demonstrate evidence of infection with tick-borne pathogens. Antibody Capture EIA is an enzyme-based test developed to identify various isotypes of the host immune response. Other methodologies to identify specific immune response evidence of infection include Western Immunoblotting (WB) and Immunofluorescence (IFA). Polymerase Chain Reaction (PCR), also referred to as nucleic acid testing, is a very powerful molecular technique that – in contrast to identifying antibodies – directly demonstrates the presence of the pathogen’s specific DNA sequences in an appropriate clinical specimen.

For services utilizing polymerase chain reaction (PCR) technology:

PCR testing is performed pursuant to an agreement with Roche Molecular Systems, Inc.

For services utilizing immunofluorescent technology: 

This service and the resulting deliverables are provided under an intellectual property license from Life Technologies Corporation that authorizes the use of such intellectual property in connection with the purchased service solely for the purpose of providing human medical or diagnostic testing, analysis or screening services, including use for the purpose of guiding therapeutic strategy or determining outcome or providing clinical information or clinical analysis in return for compensation on a per-test basis, within the parameters set forth in the accompanying product literature. The provision of this service is conditioned on the buyer not using this service for any purpose not expressly authorized. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com.